Opioid analgesic - Sarfez

Drug Profile

Opioid analgesic - Sarfez

Alternative Names: Mu-receptor agonist - Sarfez pipeline, November 2017

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sarfez Pharmaceuticals
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 24 Nov 2017 Preclinical trials in Migraine in USA before November 2017 (Sarfez pipeline, November 2017)
  • 24 Nov 2017 Sarfez announces intention to submit NDA to US FDA for Migraine in the second quarter of 2020 (Sarfez pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top